Biotechnology

uniQure's upsized $259M offering signals massive investor confidence, fueling its Huntington's therapy, AMT-130, and reshaping the gene therapy landscape.

New data on a once-weekly drug and a novel combination therapy signal a major shift in treating achondroplasia, moving the focus from height to quality of life.

Beyond the hype, NextRise 2026 in Seoul delivered real results, connecting 540+ startups with global giants and revealing South Korea's deep-tech ambitions.

A new DARPA-backed technology from ARA uses biological principles to create life-saving medicines on-demand, bypassing fragile supply chains for the military.

Valneva's latest AGM wasn't just procedural. A new expert Chair and key operational shifts reveal a company doubling down on its late-stage vaccine strategy.

Nomic Bio and the HESI OASIS Consortium partner to map liver toxicity using proteomics, fueling AI models to make drug development safer and more ethical.

Oramed leverages a strategic pivot into a diversified operator, seeing massive gains from its Alpha Tau stake and securing entry into the Russell 2000 index.

A new partnership brings genetically engineered probiotics to Gurney's Montauk. We explore the science, strategy, and ethics of the burgeoning "pre-covery" trend.

Chicago is moving beyond headlines, orchestrating a deliberate strategy to become a global health innovation leader. The upcoming Venture Summit is more than an event; it's the city's crucible for forging a new economic identity.

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

Biotech innovator Ernexa Therapeutics launches a new CEO platform, betting that open communication can help it solve cell therapy's biggest challenge: cost.

Following promising clinical data, biotech firm Immunis unveils a new brand identity, signaling a strategic shift toward multi-pathway biologics for healthy aging.

An independent safety board just gave Medera's novel gene therapy for a stubborn form of heart failure a major endorsement, de-risking its path to the FDA.

A novel membrane technology promises to speed up production of next-gen medicines by solving a critical, energy-intensive bottleneck in pharmaceutical manufacturing.

By combining vast datasets with patient-driven advocacy, a new alliance offers hope for angiosarcoma patients and a new model for rare disease research.

NeuroSense's PrimeC shows intriguing biomarker activity against Alzheimer's, targeting multiple disease pathways. Is this the shift away from single-target drugs?

Hatch BioFund's new investment in Princeton spinout Optimeos funds a novel nanoparticle platform that could solve one of medicine's biggest challenges.

A Virginia nonprofit's AI platform, backed by Pentagon funding, has decoded the deadly impact of radiation on the gut, paving the way for new countermeasures.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

A new partnership promises a less painful way to deliver cancer immunotherapy. We dive into the tech, the market, and why this is a key strategic play.